Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04731519 · ClinicalTrials.gov registry record · NA

Development of a Recovery Oriented Treatment for Post-Acute Suicidal Episode (PASE) Veterans

A NA study of Suicide, sponsored by VA Office of Research and Development.

Recruiting
Registry status
NA
Development phase
57
Enrollment target
1
Study location

NCT04731519: Recruiting NA study of Suicide, sponsored by VA Office of Research and Development.

NCT04731519 is a NA study of Suicide that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 57 participants, below the 6,989-participant average among 92 other Suicide trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04731519, a NA study of Suicide, is actively recruiting participants, sponsored by VA Office of Research and Development.

RECRUITING
Registry status
NA
Development phase
57 participants
Enrollment target
1
Study location

Study Summary

Mental health care for Veterans with suicidal symptoms is of paramount import to the VA. Unfortunately, VA suicide reports show suicide rates increasing, suggesting a need for enhancing current VA suicide mental health care efforts. While several psychotherapeutic treatments exist for acute suicidality, there are few treatments designed to help Veterans following an acute suicidal episode (Post-Acute Suicidal Episode; PASE), particularly after acute risk declines but when they still have ongoing mental health needs and, at times, long-term suicidal symptoms. Available suicide treatments are not designed to promote the recovery and rehabilitation of PASE Veterans. This is a significant gap in comprehensive suicide-focused mental health care. One avenue to close this gap lies through the development of a recovery-focused psychotherapy for PASE Veterans. Developing recovery-oriented care, "a process of change through which individuals improve their health and wellness, live a self-directed life, and strive to reach their full potential" is a VA priority; however, available treatments for suicidal Veterans do not place a strong focus on recovery. Decades of research have shown the importance of increasing Veterans hopefulness about the future, developing a positive self-identity, promoting Veterans' sense of self-empowerment and improving relationships. Continuous Identity-Cognitive Therapy (CI-CT) is a promising new manualized suicide intervention focused on improving Veterans sense of their life story and personal future, with goals similar to recovery-oriented care. The proposed study will assess and enhance the CI-CT treatment materials using Veteran feedback and acceptability and feasibility data. Then, with the guidance of scientific and Veteran consumer advisory boards, use these results to update the treatment. Findings will be used to make an updated adaptation of the treatment materials and to develop a research protocol for a pilot RCT of CI-CT for PASE Vete

Primary Outcome

The RAS is a 41-item self-report measure using a 5-point Likert scale with outcome scores ranging from 1-5 and increasing scores indicating better outcomes. Sample items include: 'I have a desire to succeed.' and 'I have goals in life that I want to reach.' Factor analysis identified five factors: personal confidence and hope, willingness to ask for help, goal and success orientation, reliance on others, and not being dominated by symptoms (Salzer \& Brusilovskiy, 2014). Narrative reviews of rec

Conditions Studied

Interventions

  • BEHAVIORAL Continuous Identity Cognitive Therapy (CI-CT)
  • BEHAVIORAL General Health Education

Study Locations (1)

New York

  • James J. Peters VA Medical Center, Bronx, NY - The Bronx

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2022-02-22
Est. Completion 2027-03-17
Phase NA
VA Office of Research and Development

1,668 total trials

What NCT04731519 shows while recruiting

NCT04731519 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 6,989-participant average among 92 other Suicide trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Suicide appearing as the primary indexed condition, and to 2 interventions - of which Continuous Identity Cognitive Therapy (CI-CT) is the first listed.

NCT04731519 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT04731519 about?

NCT04731519 is a clinical study titled "Development of a Recovery Oriented Treatment for Post-Acute Suicidal Episode (PASE) Veterans". Mental health care for Veterans with suicidal symptoms is of paramount import to the VA. Unfortunately, VA suicide reports show suicide rates increasing, suggesting a need for enhancing current VA suicide mental health care efforts. While several psychotherapeutic treatments exist for acute suicidal...

What is the current status of trial NCT04731519?

This trial is currently recruiting. It is a NA study. The enrollment target is 57 participants. The study started on 2022-02-22. Estimated completion is 2027-03-17.

What conditions does trial NCT04731519 study?

This clinical trial studies the following conditions: Suicide.

What interventions are being tested in trial NCT04731519?

The interventions under investigation include: Continuous Identity Cognitive Therapy (CI-CT) (BEHAVIORAL), General Health Education (BEHAVIORAL).

Who is sponsoring clinical trial NCT04731519?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04731519 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Suicide

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04731519's enrollment target sits among peer trials

57 69th of 92 higher than 23 of 92 other Suicide trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Suicide trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03521830 · 57 participants · Phase 2

    Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

  • NCT03587701 · 57 participants · Phase 2

    Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

  • NCT04104126 · 57 participants · NA

    Blood Flow Restriction Therapy in Achilles Injury

  • NCT04703842 · 57 participants · Phase 1

    Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04731519, the US trial registry maintained by the National Library of Medicine. NCT04731519 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.